文献速递肾小球疾病

硫辛酸使用者与非使用者的NELL1膜性肾病特征与结局

Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers.
PubMed 文献 · Kidney Int Rep · 2024-02-24

该多机构回顾性研究分析了70例NELL1膜性肾病患者,发现36%与硫辛酸相关,27%与重度非甾体抗炎药使用相关。中位随访11个月,72%达到完全或部分缓解;硫辛酸相关者且随访≥6个月缓解率达91%。多因素分析显示原发性NELL1膜性肾病和肾小管萎缩/间质纤维化程度更高者缓解可能性更低,而完全缓解与硫辛酸使用相关。

要点

  • NELL1膜性肾病中硫辛酸相关占36%,停药可能是首选治疗。
  • 硫辛酸相关且随访≥6个月者缓解率高达91%。
  • 原发性NELL1膜性肾病和间质纤维化程度高者缓解率更低。

核心结论

  • 研究强化了硫辛酸与NELL1膜性肾病的关联,提示停用硫辛酸而不使用免疫抑制可作为一线治疗考虑。

研究设计与样本

  • 回顾性多机构队列研究,纳入3个机构的70例NELL1膜性肾病患者,中位年龄66岁,53%为男性,中位蛋白尿5.9 g/d。

主要发现

  • NELL1膜性肾病与硫辛酸(36%)、重度非甾体抗炎药使用(27%)、自身免疫病(23%)、恶性肿瘤(近期10%,任何23%)、汞暴露(1%)相关,11%无已知继发关联。
  • 中位随访11个月,72%达到完全或部分缓解;硫辛酸相关且随访≥6个月者缓解率为91%。
  • 多因素分析中,原发性NELL1膜性肾病(调整OR 19.7,P=0.01)和肾小管萎缩/间质纤维化程度增加(调整OR 1.1,P=0.01)与任何缓解可能性更低相关。
  • 完全缓解与硫辛酸使用(调整OR 10.9,P=0.04,95%CI 1.2-100)和较低间质纤维化程度(调整OR 0.79,P=0.16,95%CI 0.66-0.96)相关。

临床怎么用

  • 对NELL1膜性肾病患者应详细询问硫辛酸暴露史,若相关可考虑停用硫辛酸而不立即使用免疫抑制。
  • 肾活检提示间质纤维化程度较高者缓解可能性较低,需密切随访并个体化治疗。

局限性

  • 回顾性研究设计,样本量有限,随访时间较短,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Neural epidermal growth factor like 1 membranous nephropathy (NELL1 MN) is associated with various secondary etiologies. However, previous studies on the frequency of these associations and their impact on outcomes are limited. We report a large multiinstitutional series of patients with NELL1 MN with a focus on secondary associations, pathology findings, and their impact on outcome. METHODS: We retrospectively reviewed clinicopathologic features of NELL1 MN from 3 institutions and analyzed clinical and histologic associations with outcome. RESULTS: Of 70 patients, 53% were male with a median age of 66 years; median proteinuria was 5.9 g/d. NELL1 MN was associated with lipoic acid (36%), heavy nonsteroidal antiinflammatory drug (NSAID) use (27%), autoimmune disease (23%), malignancy (10% recent, 23% any), mercury exposure (1%), and 11% had no known secondary association. At median follow-up of 11 months, 72% achieved complete or partial remission. Remission rate was 91% in patients with lipoic acid-associated NELL1 MN and ≥6 months of follow-up. On multivariable analyses, patients with primary NELL1 MN (adjusted odds ratio [OR]: 19.7, P = 0.01) and increasing degree of tubular atrophy and interstitial fibrosis (IFTA) (adjusted OR 1.1, P = 0.01) were less likely to achieve any remission, whereas complete remission (CR) was associated with lipoic acid use (adjusted OR: 10.9, P = 0.04, 95% confidence interval [CI]: 1.2-100) and lesser degrees of IFTA (adjusted OR: 0.79, P = 0.16, 95% CI: 0.66-0.96). CONCLUSION: Our findings strengthen the association between lipoic acid and NELL1 MN. Furthermore, our findings suggest that discontinuation of lipoic acid without immunosuppression should be considered as the first-line treatment.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Avasare RS, Clark S, Spain RI, et al. Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers. Kidney Int Rep. 2024. PMID: 38707817. doi:10.1016/j.ekir.2024.02.1401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。